The potential mechanism of Aidi injection against neuroblastoma-an investigation based on network pharmacology analysis

Shuyang Dai; Yaoyao Gu; Yong Zhan; Jie Zhang; Lulu Xie; Yi Li; Yifei Lu; Ran Yang; Enqing Zhou; Deqian Chen; Songbin Liu; Shan Zheng; Zhaopeng Shi; Kuiran Dong; Rui Dong

doi:10.3389/fphar.2024.1310009

The potential mechanism of Aidi injection against neuroblastoma-an investigation based on network pharmacology analysis

Front Pharmacol. 2024 Jan 19:15:1310009. doi: 10.3389/fphar.2024.1310009. eCollection 2024.

Authors

Shuyang Dai^#¹, Yaoyao Gu^#¹, Yong Zhan^#¹, Jie Zhang¹, Lulu Xie¹, Yi Li¹, Yifei Lu¹, Ran Yang¹, Enqing Zhou¹, Deqian Chen¹, Songbin Liu², Shan Zheng¹, Zhaopeng Shi³, Kuiran Dong¹, Rui Dong¹

Affiliations

¹ Shanghai Key Laboratory of Birth Defect, Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, China.
² Department of Anesthesiology, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
³ Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, School of Medicine, Basic Medical Institute, Shanghai Jiao Tong University, Shanghai, China.

^# Contributed equally.

Abstract

Background: Aidi injection, a classic traditional Chinese medicine (TCM) formula, has been used on a broader scale in treating a variety of cancers. In this study, we aimed to explore the potential anti-tumor effects of Aidi injection in the treatment of neuroblastoma (NB) using network pharmacology (NP). Methods: To elucidate the anti-NB mechanism of Aidi injection, an NP-based approach and molecular docking validation were employed. The compounds and target genes were collected from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine (BATMAN-TCM) database. The protein-protein interaction network was constructed using the STRING database. clusterProfiler (R package) was utilized to annotate the bioinformatics of hub target genes. The gene survival analysis was performed on R2, a web-based genomic analysis application. iGEMDOCK was used for molecular docking validation, and GROMACS was utilized to validate molecular docking results. Furthermore, we investigated the anticancer effects of gomisin B and ginsenoside Rh2 on human NB cells using a cell viability assay. The Western blot assay was used to validate the protein levels of target genes in gomisin B- and ginsenoside Rh2-treated NB cells. Results: A total of 2 critical compounds with 16 hub target genes were identified for treating NB. All 16 hub genes could potentially influence the survival of NB patients. The top three genes (EGFR, ESR1, and MAPK1) were considered the central hub genes from the drug-compound-hub target gene-pathway network. The endocrine resistance and estrogen signaling pathways were identified as the therapeutic pathways using the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Gomisin B and ginsenoside Rh2 showed a good binding ability to the target protein in molecular docking. The results of cell experiments showed the anti-NB effect of gomisin B and ginsenoside Rh2. In addition, the administration of gomisin B over-regulated the expression of ESR1 protein in MYCN-amplified NB cells. Conclusion: In the present study, we investigated the potential pharmacological mechanisms of Aidi against NB and revealed the anti-NB effect of gomisin B, providing clinical evidence of Aidi in treating NB and establishing baselines for further research.

Keywords: Aidi injection; molecular docking; network pharmacology; neuroblastoma; pharmacological mechanisms.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Cyrus Tang Foundation (No. ZSBK0070), Shanghai Municipal Key Clinical Specialty (No. shslczdzk05703), the National Natural Science Foundation of China (No. 82072782, 82172852), the Shanghai Hospital Development Center Foundation (SHDC12020125), and the Shanghai Municipal Health Commission (No. EK112520180301 and 2020YJZX0119). This work was also supported in part by the Medical Science Data Center in Shanghai Medical College of Fudan University.